Canntab awarded Health Canada cannabis research licence

TORONTO — Canntab Therapeutics Ltd., a manufacturer of cannabinoid and terpene blends in hard pill form for therapeutic application, announced Feb. 24 that Health Canada has granted the firm a cannabis research licence for the purpose of continuing research and development at its Markham, Ont., facility.

Canntab intends, following receipt of a standard processing licence and sale for medical purposes licence from Health Canada, to produce various hard pill oral delivery formulations including extended release, instant release and bi-layered hard pills.

Jeff Renwick, co-founder and CEO of Canntab, explained that once the processing and sale licence are received, the firm will have products ready for distribution and sale. He said in a statement, “Our facility is fully built-out and we are excited to prepare our final formulations for submission. We are equally excited with the prospect of continuing research and development in full force at our Markham facility.”